

Step Therapy Criteria
SAHP Premier
Effective: 01/01/2023

ANTIDEPRESSANTS - (S)

Products Affected

- Emsam
- Fetzima
- Fetzima Titration Pack
- Sertraline Hydrochloride CAPS

Details

Criteria	Trial of two generics of the following formulary products: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline (tablet or solution), venlafaxine. Approve for continuation of prior therapy.
-----------------	---

ATINIC KERATOSIS - S

Products Affected

- Diclofenac Sodium GEL 3%

Details

Criteria	Trial of either topical fluorouracil or topical imiquimod
-----------------	---

ATYPICAL ANTIPSYCHOTICS - (S)

Products Affected

- Fanapt
- Fanapt Titration Pack
- Lybalvi
- Secuado
- Vraylar

Details

Criteria	Pending CMS Review
-----------------	--------------------

DPP4 INHIBITORS NON-PREFERRED - S

Products Affected

- Kombiglyze Xr

Details

Criteria	Trial of one of the following: Janumet, Janumet XR, Januvia, Jentadueto, Jentadueto XR, or Tradjenta
-----------------	--

FILGRASTIM - (S)

Products Affected

- Granix
- Neupogen

Details

Criteria	Trial or intolerance to Zarxio
----------	--------------------------------

GLP1 AGONISTS - S

Products Affected

- Ozempic
- Trulicity
- Victoza

Details

Criteria	Trial of one of the following generic formulary metformin or metformin combinations: metformin, metformin ER, glipizide-metformin, glyburide-metformin, pioglitazone-metformin. Ozempic (semaglutide), Trulicity (dulaglutide), Victoza (liraglutide): Step requirements do not apply to members with type 2 diabetes and multiple cardiovascular risk factors or established cardiovascular disease.
-----------------	---

INVEGA HAFYERA THERAPY - S

Products Affected

- Invega Hafyera

Details

Criteria	Trial of one of the following: Invega Sustenna or Invega Trinza. Step applies to new starts only. Approve for continuation of prior therapy.
-----------------	--

LEUKOTRIENE MODIFIERS - (S)

Products Affected

- Zileuton Er

Details

Criteria	Trial of generic montelukast or generic zafirlukast
-----------------	---

NAMZARIC - S

Products Affected

- Namzarin

Details

Criteria	Trial of generic memantine extended-release
-----------------	---

PD AGENTS -(S)

Products Affected

- Neupro

Details

Criteria	Trial of one of the following generic formulary dopamine agonist agent: pramipexole, ropinirole
-----------------	--

RELISTOR-(S)

Products Affected

- Relistor

Details

Criteria	Trial of lubiprostone or lactulose
-----------------	------------------------------------

Index Of Drugs

A		
Antidepressants - (s).....	1	
Atinic Keratosis - S	2	
Atypical Antipsychotics - (s).....	3	
D		
Diclofenac Sodium.....	2	
Dpp4 Inhibitors Non-preferred - S	4	
E		
Emsam.....	1	
F		
Fanapt.....	3	
Fanapt Titration Pack	3	
Fetzima.....	1	
Fetzima Titration Pack	1	
Filgrastim - (s).....	5	
G		
Glp1 Agonists - S	6	
Granix.....	5	
I		
Invega Hafyera	7	
Invega Hafyera Therapy - S	7	
K		
Kombiglyze Xr.....	4	
L		
Leukotriene Modifiers - (s).....	8	
		Lybalvi.....3
		N
		Namzaric.....9
		Namzaric - S
		9
		Neupogen
		5
		Neupro.....10
		O
		Ozempic
		6
		P
		Pd Agents -(s)
		10
		R
		Relistor.....11
		Relistor-(s)
		11
		S
		Secuado.....3
		Sertraline Hydrochloride.....1
		T
		Trulicity.....6
		V
		Victoza
		6
		Vraylar
		3
		Z
		Zileuton Er
		8